AJMC - Change is Coming

AJMC - Change is Coming

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Zhanna Jumadilova, MD, MBA

Articles by Zhanna Jumadilova, MD, MBA

Persistence With Overactive Bladder Pharmacotherapy in a Medicaid Population

ByFadia T. Shaya, PhD, MPH,Steven Blume, MS,Anna Gu, MA,Teresa Zyczynski, PharmD, MBA, MPH,Zhanna Jumadilova, MD, MBA

July 15th 2005

Medical Costs After Initiation of Drug Treatment for Overactive Bladder: Effects of Selection Bias on Cost Estimates

ByNicole M. Nitz, PhD,Zhanna Jumadilova, MD, MBA,Theodore Darkow, PharmD,Jennifer R. Frytak, PhD,Tamara Bavendam, MD

July 15th 2005

Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder

BySujata Varadharajan, MS,Zhanna Jumadilova, MD, MBA,Prafulla Girase, MS,Daniel A. Ollendorf, MPH

July 15th 2005

Urinary Incontinence in the Nursing Home: Resident Characteristics and Prevalence of Drug Treatment

ByZhanna Jumadilova, MD, MBA,Teresa Zyczynski, PharmD, MBA, MPH,Barbara Paul, MD,Siva Narayanan, MS, MHS

July 15th 2005

Treatment of Overactive Bladder: A Model Comparing Extended-release Formulations of Tolterodine and Oxybutynin

ByEleanor M. Perfetto, PhD,Prasun Subedi, MS,Zhanna Jumadilova, MD, MBA

July 15th 2005

Latest Updated Articles

Persistence With Overactive Bladder Pharmacotherapy in a Medicaid Population
Published: July 15th 2005 | Updated:
Medical Costs After Initiation of Drug Treatment for Overactive Bladder: Effects of Selection Bias on Cost Estimates
Published: July 15th 2005 | Updated:
Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder
Published: July 15th 2005 | Updated:
Urinary Incontinence in the Nursing Home: Resident Characteristics and Prevalence of Drug Treatment
Published: July 15th 2005 | Updated:
Treatment of Overactive Bladder: A Model Comparing Extended-release Formulations of Tolterodine and Oxybutynin
Published: July 15th 2005 | Updated:

Trending on AJMC

CLL Breakthrough: 100% Efficacy Reported for VenR Retreatment

AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule

Trulicity, Botox Headline Drugs Included in the Third Cycle of Medicare Price Negotiations

New Dermatologic Therapies Make Waves at Maui Derm 2026

Advances in Pediatric Dermatology Spotlight Diagnostic Precision and New Systemics

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.